The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Findings from a trial of golcadomide ± rituximab in R/R DLBCL
Julio Chavez, MD, Moffitt Cancer Center, Tampa, FL, comments on a trial investigating the combination of golcadomide and rituximab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Dr Chavez reports high overall response rates with a favorable side effect profile, offering a treatment option for this patient population that can be administered in an outpatient setting. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
This is the other part of the study. We have two parts, the follicular lymphoma part, this is the diffuse large cell lymphoma part. And also, it’s also very remarkable, the same combination of golcadomide and rituximab. Lenalidomide was given in two weeks on, two weeks off, a little different than lenalidomide in combination with rituximab. Population also was heavily pretreated about three to four lines of therapy, about almost 50% patients had prior CAR T-cell therapy, about 20% had bispecific antibodies, so very high-risk patients in which their survival is probably between five to six months...
This is the other part of the study. We have two parts, the follicular lymphoma part, this is the diffuse large cell lymphoma part. And also, it’s also very remarkable, the same combination of golcadomide and rituximab. Lenalidomide was given in two weeks on, two weeks off, a little different than lenalidomide in combination with rituximab. Population also was heavily pretreated about three to four lines of therapy, about almost 50% patients had prior CAR T-cell therapy, about 20% had bispecific antibodies, so very high-risk patients in which their survival is probably between five to six months. So in those patients, especially with a higher dose of golcadomide, 0.4 milligrams, we see close to 60% overall response rates and about 30 to 35% CR rates. I think the efficacy was remarkable. Again, similar to follicular lymphoma, the most significant side effect was neutropenia that was treated with growth factors. So I think we showed that this activity even in high-risk patients, you know post-CAR-T, post-bispecific, lenalidomide treated, I think has an opportunity to fill the gap on patients who have no treatment options for diffuse large cell lymphoma. It’s an oral medication, outpatient. Those are also the benefits of it.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Merck: Research Funding; Lilly: Honoraria, Speakers Bureau; Janssen: Honoraria; AstraZeneca: Consultancy; Allogene: Consultancy; Cellectis: Consultancy; GenMab: Consultancy, Research Funding; Abbvie: Consultancy; BeiGene: Consultancy, Honoraria, Speakers Bureau; ADC Therapeutics: Consultancy; Novartis: Consultancy; Kite, a Gilead Company: Consultancy.
